Last updated: 11/07/2018 14:47:43
An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of 49653 When Administered Once or Twice Daily in Combination with Metformin to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM)
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of 49653 When Administered Once or Twice Daily in Combination with Metformin to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM)
Trial description: An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of 49653 When Administered Once or Twice Daily in Combination with Metformin to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM)
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Rood J, et al. The Incremental Benefit of Adding Metformin to Patients Inadequately Controlled on Maximal Rosiglitazone Monotherapy (8 mg/day) Diabetes Metab 2003; 29:4S249. Poster 2283 presented at IDF.
Rood J, et al. The Incremental Benefit of Adding Metformin to Patients Inadequately Controlled on Maximal Rosiglitazone Monotherapy. Diabetes 2003; 52 (Suppl 1):A131-132. Poster 564-P presented at ADA.
Medical condition
Diabetes Mellitus, Type 2
Product
rosiglitazone
Collaborators
Not applicable
Study date(s)
September 1997 to September 2000
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2000-29-09
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website